Manipulating MiRNA Expression: a Novel Approach for Colon Cancer Prevention and Chemotherapy

Current Pharmacology Reports

Volumn 1, Issue 3, 2015, Pages 141-153

  Ramalingam, Satish ^a   Subramaniam, Dharmalingam ^a   Anant, Shrikant ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Drug delivery; MiRNAs; Nanoparticles; OncomiRs; Phytochemicals; Vitamins

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; APC PROTEIN; CURCUMIN; EPIGALLOCATECHIN GALLATE; GENISTEIN; HYALURONIC ACID; ISOTHIOCYANIC ACID; K RAS PROTEIN; LENTIVIRUS VECTOR; LIPID EMULSION; LIPOSOME; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 135A; MICRORNA 143; MICRORNA 145; MICRORNA 189; MICRORNA 200; MICRORNA 21; MICRORNA 31; MICRORNA LET 7; NANOPARTICLE; PEPTIDE NUCLEIC ACID; PROTEIN P53; RESVERATROL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; WNT PROTEIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL CANCER; DIET; DNA MODIFICATION; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; HUMAN; METASTASIS; NONHUMAN; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA GENE; SPONGE CONSTRUCT; STABLE NUCLEIC ACID LIPID PARTICLE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

EID: 85015497609     PISSN: None     EISSN: 2198641X     Source Type: Journal    
DOI: 10.1007/s40495-015-0020-3     Document Type: Review

References (150)

1. Zhou X, Yang PC. MicroRNA: a small molecule with a big biological impact. Micro RNA. 2012;1(1):1.
2. Perron MP, Provost P. Protein interactions and complexes in human microRNA biogenesis and function. Front Biosci: J Virtual Libr. 2008;13:2537–47.
3. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537–61.
4. Rajewsky N. L (ou)sy miRNA targets? Nat Struct Mol Biol. 2006;13(9):754–5.
5. Griffiths-Jones S. The microRNA registry. Nucleic Acids Res. 2004;32(Database issue):D109–11.
6. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell. 2004;16(6):861–5.
7. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.
8. Krutzfeldt J et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–9.
9. Huppi K et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res: MCR. 2008;6(2):212–21.
10. Pomerantz MM et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009;69(13):5568–74.
11. Wu W. Modulation of microRNAs for potential cancer therapeutics. Methods Mol Biol. 2011;676:59–70.
12. Matsushima K et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 2011;9:30.
13. Gibbs WW. The unseen genome: gems among the junk. Sci Am. 2003;289(5):26–33.
14. Fiorucci G et al. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem. 2012;19(4):461–74.
15. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10A):1902–10.
16. Ying SY, Chang CP, Lin SL. Intron-mediated RNA interference, intronic microRNAs, and applications. Methods Mol Biol. 2010;629:205–37.
17. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA. 2003;9(2):175–9.
18. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A. 2007;104(45):17719–24.
19. Lee Y et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60.
20. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006;13(12):1097–101.
21. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17(3):118–26.
22. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
23. Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role. Cell. 2010;140(4):445–9.
24. Han L, Witmer PD, Casey E, Valle D, Sukumar S. DNA methylation regulates MicroRNA expression. Cancer Biol Therapy. 2007;6(8):1284–8.
25. Kulshreshtha R et al. A microRNA signature of hypoxia. Mol Cell Biol. 2007;27(5):1859–67.
26. Fiedler SD, Carletti MZ, Hong X, Christenson LK. Hormonal regulation of MicroRNA expression in periovulatory mouse mural granulosa cells. Biol Reprod. 2008;79(6):1030–7.
27. Davis CD, Ross SA. Evidence for dietary regulation of microRNA expression in cancer cells. Nutr Rev. 2008;66(8):477–82.
28. Han J et al. Posttranscriptional crossregulation between Drosha and DGCR8. Cell. 2009;136(1):75–84.
29. Chendrimada TP et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005;436(7051):740–4.
30. Han J et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006;125(5):887–901.
31. Meister G et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15(2):185–97.
32. Liu J et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305(5689):1437–41.
33. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515–24.
34. Brengues M, Teixeira D, Parker R. Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies. Science. 2005;310(5747):486–9.
35. Maroney PA, Yu Y, Fisher J, Nilsen TW. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol. 2006;13(12):1102–7.
36. Maroney PA, Yu Y, Nilsen TW. MicroRNAs, mRNAs, and translation. Cold Spring Harb Symp Quant Biol. 2006;71:531–5.
37. Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol: WJG. 2014;20(22):6786–808. In this review, the author’s have highlighted key findings in the field of colorectal cancer and discussed various aspects from prevention to personalized medicine. In addition, they have provided information on recent advances in molecular biology and the genetic classifications of colorectal cancer. Furthermore, they have provided insights on ways to improve the colon cancer treatment in the coming years.
38. Bouyssou JM et al. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014;1845(2):255–65.
39. Huang J et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47(4):277–86.
40. Kasinski AL, et al. (2014) A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene.
41. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012;59(4):467–74.
42. Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med. 2012;10:128.
43. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102.
44. Nosho K et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis. 2014;35(4):776–83.
45. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nature reviews. Cancer. 2006;6(4):259–69.
46. Sha D et al. Association study of the let-7 miRNA-complementary site variant in the 3′ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(12):3319–27.
47. King CE et al. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene. 2011;30(40):4185–93.
48. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006;29(5):903–6.
49. Deng J et al. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Comm. 2014;443(3):789–95.
50. Oue N et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer J Int Cancer. 2014;134(8):1926–34.
51. Roy S, Yu Y, Padhye SB, Sarkar FH, Majumdar AP. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One. 2013;8(7):e68543.
52. Faltejskova P et al. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Color Dis. 2012;27(11):1401–8.
53. Zhang J et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011;117(1):86–95.
54. Zhu H et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res: MCR. 2011;9(7):960–75.
55. Yu G et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J Surg Oncol. 2012;106(3):232–7.
56. Tsuchida A et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci. 2011;102(12):2264–71.
57. Peric D, Chvalova K, Rousselet G. Identification of microprocessor-dependent cancer cells allows screening for growth-sustaining micro-RNAs. Oncogene. 2012;31(16):2039–48.
58. Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28(12):3091–100.
59. Olive V et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839–49.
60. Tili E et al. GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Res. 2010;38(21):7673–88.
61. Humphreys KJ et al. Dietary manipulation of oncogenic microRNA expression in human rectal mucosa: a randomized trial. Cancer Prev Res. 2014;7(8):786–95. Intake of high red meat is associated with increased colorectal cancer risk. In addition, elevated oncogenic microRNAs have been shown to induce tumorigenesis. In this article, for the first time, it was demonstrated that dietary manipulation of microRNA by butyrylated resistant starch supplementation reduced the risk of human rectal cancer associated with high red meat intake in a randomized trial.
62. Xiao J et al. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol. 2007;212(2):285–92.
63. Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers. 2010;7(3):536–42.
64. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–6.
65. Gumireddy K et al. Small-molecule inhibitors of microrna miR-21 function. Angew Chem. 2008;47(39):7482–4.
66. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193–9.
67. Cole KA et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res: MCR. 2008;6(5):735–42.
68. Ng EK et al. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer. 2009;101(4):699–706.
69. Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science. 2007;318(5848):271–4.
70. Kauppinen S, Vester B, Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. Handb Exp Pharmacol. 2006;173:405–22.
71. Valeri N et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010;107(49):21098–103.
72. Dias BG et al. Amygdala-Dependent Fear Memory Consolidation via miR-34a and Notch Signaling. Neuron. 2014;83(4):906–18.
73. Bu P et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell. 2013;12(5):602–15.
74. Veldhoen S, Laufer SD, Restle T. Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci. 2008;9(7):1276–320.
75. Fabbri E et al. Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). Chem Med Chem. 2011;6(12):2192–202.
76. Mudduluru G et al. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011;30(25):2888–99.
77. Nakagawa Y, Iinuma M, Naoe T, Nozawa Y, Akao Y. Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem. 2007;15(16):5620–8.
78. Kota J et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005–17.
79. Trang P et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29(11):1580–7.
80. Bonci D et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271–7.
81. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Therapy: J Am Soc Genet Therapy. 2013;21(5):986–94.
82. Li L et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Therapy: J Am Soc Genet Therapy. 2012;20(12):2326–34.
83. Pramanik D et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011;10(8):1470–80.
84. Piao L et al. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Therapy: J Am Soc Genet Therapy. 2012;20(6):1261–9.
85. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Therapy: J Am Soc Genet Therapy. 2010;18(9):1650–6.
86. Ando H et al. Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy. J Genet Med. 2013;15(1):20–7. MicroRNAs appears to be the promising targets for treatment of cancer. Furthermore, various studies have demonstrated that miRNAs mediate angiogenesis and metastasis by regulating the expression of target genes. In this study, they have developed a miRNA delivery system and demonstrated its ability to inhibit angiogenesis and to suppress tumor growth.
87. Asai T et al. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery. Bioconjug Chem. 2011;22(3):429–35.
88. Trang P et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Therapy: J Am Soc Genet Therapy. 2011;19(6):1116–22.
89. Costa PM et al. Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. Mol Therapy Nucleic Acids. 2013;2:e100.
90. de Antonellis P et al. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedeberg’s Arch Pharmacol. 2013;386(4):287–302.
91. Yang YP et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012;33(5):1462–76.
92. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387–422.
93. Babar IA et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A. 2012;109(26):E1695–704.
94. Ren Y et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed. 2010;21(3):303–14.
95. Costa PM, Pedroso de Lima MC. MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals. 2013;6(10):1195–220.
96. Parasramka MA, Ho E, Williams DE, Dashwood RH. MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog. 2012;51(3):213–30.
97. Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat: Rev Commentaries Antimicrob Anticancer Chemother. 2010;13(3):57–66.
98. Milenkovic D, Jude B, Morand C. miRNA as molecular target of polyphenols underlying their biological effects. Free Radic Biol Med. 2013;64:40–51.
99. Wu Y, et al. (2014) Association between vitamin A, retinol intake and blood retinol level and gastric cancer risk: A meta-analysis. Clinical nutrition.
100. Suphakarn VS, Newberne PM, Goldman M. Vitamin A and aflatoxin: effect on liver and colon cancer. Nutr Cancer. 1983;5(1):41–50.
101. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol. 2002;41(1):41–55.
102. Rossi A et al. Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. BMC Res Notes. 2010;3:24.
103. Garzon R et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007;26(28):4148–57.
104. Garland CF et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96(2):252–61.
105. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 2006;35(2):217–20.
106. Padi SK, Zhang Q, Rustum YM, Morrison C, Guo B. MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. Gastroenterology. 2013;145(2):437–46.
107. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle. 2009;8(5):736–41.
108. Peng X et al. Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J Cell Biochem. 2010;110(6):1324–33.
109. Bostick RM et al. Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women’s Health Study. Cancer Res. 1993;53(18):4230–7.
110. Wang XF, Witting PK, Salvatore BA, Neuzil J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun. 2005;326(2):282–9.
111. Gaedicke S et al. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett. 2008;582(23–24):3542–6.
112. Zhang P, Suidasari S, Hasegawa T, Yanaka N, Kato N. Vitamin B(6) activates p53 and elevates p21 gene expression in cancer cells and the mouse colon. Oncol Rep. 2014;31(5):2371–6.
113. Zhong H, et al. (2014) Association of vitamin D receptor gene polymorphism with the risk of lung cancer: a meta-analysis. Journal of receptor and signal transduction research:1–6
114. Kutay H et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99(3):671–8.
115. Peters U et al. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control: CCC. 2008;19(1):75–87.
116. Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis. 2009;30(8):1416–23.
117. Lee JI et al. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res. 2009;2(7):683–93.
118. Dashwood RH. Early detection and prevention of colorectal cancer (review). Oncol Rep. 1999;6(2):277–81.
119. Maciel-Dominguez A, Swan D, Ford D, Hesketh J. Selenium alters miRNA profile in an intestinal cell line: evidence that miR-185 regulates expression of GPX2 and SEPSH2. Mol Nutr Food Res. 2013;57(12):2195–205.
120. Davidson LA et al. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis. 2009;30(12):2077–84.
121. Farago N, Feher LZ, Kitajka K, Das UN, Puskas LG. MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes. Lipids Health Dis. 2011;10:173.
122. Sethi S, Li Y, Sarkar FH. Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets. 2013;14(10):1167–74. This review article offered the latest development on regulation of microRNAs by various natural chemotherapeutic agents. They have also provided evidence that these natural agents could inhibit cancer progression, and metastasis. In addition, these compounds will enhance drug sensitivity and reverse epithelial mesenchymal transition. This article supports the newer therapeutic approach for cancer treatment.
123. Subramaniam D et al. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PLoS One. 2011;6(2):e16958.
124. Sun M et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7(3):464–73.
125. Bao B et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One. 2011;6(3):e17850.
126. Saud SM, et al. (2014) Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression. Carcinogenesis.
127. Tili E, Michaille JJ. Resveratrol, MicroRNAs, Inflammation, and Cancer. J Nucleic Acids. 2011;2011:102431.
128. Tili E et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis. 2010;31(9):1561–6.
129. Tili E et al. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem Pharmacol. 2010;80(12):2057–65.
130. Del Follo-Martinez A, Banerjee N, Li X, Safe S, Mertens-Talcott S. Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a. Nutr Cancer. 2013;65(3):494–504.
131. Kumazaki M et al. Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells. J Nutr Biochem. 2013;24(11):1849–58.
132. Bigelow RL, Cardelli JA. The green tea catechins, (−)-Epigallocatechin-3-gallate (EGCG) and (−)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene. 2006;25(13):1922–30.
133. Saldanha SN, Kala R, Tollefsbol TO. Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp Cell Res. 2014;324(1):40–53.
134. Baselga-Escudero L et al. Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells. Nucleic Acids Res. 2014;42(2):882–92.
135. Chakrabarti M, Khandkar M, Banik NL, Ray SK. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res. 2012;1454:1–13.
136. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem. 2010;21(2):140–6.
137. Luo Y, et al. (2014) Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor-kappa B (NF-kappaB) pathway. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine.
138. Chiyomaru T et al. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS One. 2013;8(3):e58929.
139. Xia J et al. Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells. Curr Pharm Des. 2014;20(33):5348–53.
140. Zaman MS et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One. 2012;7(11):e50203.
141. Gupta P, Kim B, Kim SH, Srivastava SK. Molecular targets of isothiocyanates in cancer: recent advances. Mol Nutr Food Res. 2014;58(8):1685–707.
142. Shan Y et al. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem. 2013;24(6):1062–9.
143. Izzotti A et al. Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung. Carcinogenesis. 2010;31(5):894–901.
144. Maruthanila VL, Poornima J, Mirunalini S. Attenuation of Carcinogenesis and the Mechanism Underlying by the Influence of Indole-3-carbinol and Its Metabolite 3,3′-Diindolylmethane: A Therapeutic Marvel. Adv Pharmacol Sci. 2014;2014:832161.
145. Li Y et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010;70(4):1486–95.
146. Melkamu T, Zhang X, Tan J, Zeng Y, Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis. 2010;31(2):252–8.
147. Paik WH et al. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res. 2013;33(4):1473–81.
148. Sarkar S et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res. 2013;3(5):465–77.
149. Le V, et al. (2014) Cytotoxic Effects of Ellagitannins Isolated from Walnuts in Human Cancer Cells. Nutrition and cancer:1–11
150. Wen XY et al. Ellagitannin (BJA3121), an anti-proliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells. Phytother Res: PTR. 2009;23(6):778–84.